Tickerover
Healthcare

ANIP Stock Analysis

ANI Pharmaceuticals, Inc. · current price $72.85 (-0.90% today)

Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
★★★
Average
📊

The six-pillar scorecard

Momentum
33
In a downtrend
price trend
Growth
27
Barely growing
sales & profit growth
Quality
87
High quality
profitability & balance sheet
Valuation
75
Looks cheap
is the price fair?
Sentiment
38
Mixed views
analyst & crowd mood
Risk
74
Low risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
GrowthGrowth: 8888Near 52w highNear 52w high: 100100Earnings qualityEarnings quality: 9393FundamentalsFundamentals: 9292Analyst consensusAnalyst consensus: 7070Earnings accelerationEarnings acceleration: 8888News sentimentNews sentiment: 8282
Margin profileWhat survives each step down the income statement.
GrossGross: 60.4%60.4%OperatingOperating: 15.0%15.0%NetNet: 11.1%11.1%Free cash flowFree cash flow: 17.1%17.1%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +8.2% vs estimate+8%2026-062026-03: +57.8% vs estimate+58%2026-032025-12: +17.9% vs estimate+18%2025-122025-09: +15.2% vs estimate+15%2025-09
👁

Hype Check

Reading ANIP’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading ANIP’s filings…

📣

Latest earnings

LAST EARNINGS ANI Pharmaceuticals, Inc. (ANIP)

Latest earnings

EPS
$2.04 vs $1.77 est · +15.2% vs estimate BEAT
Revenue
$266.0M · +16.8% YoY
Stock reaction (1M)
-9.4%
Beat streak
4 of last 4 quarters
💰

Valuation

P/E
15.9×
Forward P/E
7.0×
Price / Sales
1.7×
Price / Book
2.6×
EV / EBITDA
8.6×
Analyst target
$108.38
Target range
$90.00 – $121.00
Implied upside
+48.8%
🩺

Financial health

Gross margin
60.4%
Operating margin
15.0%
Net margin
11.1%
FCF margin
17.1%
Return on equity
20.5%
Debt / equity
1.05
Revenue growth YoY
+25.9%
EPS growth YoY
+191.1%
📈

Technicals

$70.1552-week range$99.50
RSI (14)
37
50-day MA
$79.55
200-day MA
$79.65
ATR (14)
2.14
Beta
0.46
1-month return
-9.4%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$2.04$1.77+15.2%Beat
2025-12-31$2.33$1.98+17.9%Beat
2026-03-31$2.05$1.30+57.8%Beat
2026-06-30$2.21$2.04+8.2%Beat
Beat 4 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.18%
Beta
0.46
📰

Latest news on ANIP

🔗

Similar stocks in Healthcare

Frequently asked

What is ANIP's Quant Score?

ANI Pharmaceuticals, Inc. (ANIP) currently has a TickerMover Quant Score of 59/100, rated ★★★ Average. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is ANI Pharmaceuticals, Inc. (ANIP) a buy?

TickerMover does not give buy or sell recommendations. ANIP scores 59/100 (★★★ Average) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is ANIP's score updated?

ANIP's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for ANIP →